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Reproducibility over a 1-month period
of
1H-MR spectroscopic imaging NAA/Cr ratios
in clinically stable multiple sclerosis patients
Abstract N-acetylaspartate/creatine
(NAA/Cr) ratios, assessed with proton
magnetic resonance spectroscopy, are
increasingly used as a surrogate
marker for axonal dysfunction and
degeneration in multiple sclerosis
(MS). The purpose of this study was to
test short-time reproducibility of
NAA/Cr ratios in patients with clini-
cally stable MS. In 35 MS patients we
analysed NAA/Cr ratios obtained with
1H-MR spectroscopic imaging at the
centrum semiovale either with lateral
ventricles partially included (group 1;
n=15) or more cranially with no
ventricles included (group 2; n=20).
To test short-term reproducibility of
the NAA/Cr measurements, patients
were scanned twice 4 weeks apart. We
determined mean NAA/Cr and Cho/
Cr ratios of 12 grey matter and 24
white matter voxels. Mean NAA/Cr
ratios of both the white and grey
matter did not change after 4 weeks.
Overall 4-week reproducibility of the
NAA/Cr ratio, expressed as coeffi-
cient of variation, was 4.8% for grey
matter and 3.5% for white matter.
Reproducibility of cranial scanning of
the ventricles was slightly better than
with cerebrospinal fluid included. Our
study shows good short-term repro-
ducibility of NAA/Cr ratio measure-
ments in the centrum semiovale,
which supports the reliability of this
technique for longitudinal studies.
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Introduction
Multiple sclerosis (MS) is a chronic disorder of the central
nervous system with inflammatory demyelination and
axonal degeneration [1]. The disease usually starts between
the ages of 20 and 40 years, and by the age of 55 years,
about half of the patients need unilateral assistance to walk
[2]. The disease progresses slowly, and clinical scales
currently used are not sensitive enough to quantify
progression [3]. Using surrogate markers of progression
can shorten the duration of clinical trials in progressive MS.
¹H-magnetic resonance spectroscopy (¹H-MRS) of the
brain in MS patients can detect changes in cell metabolites
in both focal lesions and normal-appearing white matter
(NAWM) [4]. Compared to controls, N-acetylaspartate
(NAA) concentrations in MS patients are lower both in the
lesions and in NAWM, whereas creatine (Cr) concentra-
tions are equal to slightly increased [5]. NAA is a marker of
neuroaxonal metabolism and integrity, and reductions in
the white matter are due to axonal dysfunction or loss. It
has been suggested that whole-brain NAA decline rates in
patients with MS may predict future disease course [6]. Cr
is present in neurons, astrocytes and oligodendrocytes, and
elevations in white matter of MS patients can be due to
axonal transection, astrocytic proliferation, and demyelin-
ation. Because absolute concentrations of metabolites with
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Fax: +31-50-3611707¹H-MRS are difficult to interpret, the NAA/Cr ratio is often
used as a valid surrogate marker of ‘cerebral tissue
integrity’ [5]. Decreases in NAA/Cr, which in MS patients
are found in lesions and NAWM, are indicative of
neuroaxonal disturbance, oligodendroglial disturbance, or
astrocytic proliferation. The third metabolite well obser-
vable in long TE ¹H-MRS is choline (Cho), which is
regarded as a marker of glial proliferation [7].
Next to validity, good surrogate markers need to be
reliable, especially when used for monitoring white matter
integrity in longitudinal studies. In this study we
investigated the reproducibility of NAA/Cr ratios obtained
with 2D spectroscopic imaging at two different levels of
the centrum semiovale within a time span of 4 weeks in
patients with clinically stable MS.
Materials and methods
Patients
All patients co-operated in the study with informed consent
and local medical ethical committee approval. Thirty-five
patients participated in the study. Patients were randomly
divided in two groups. All patients had clinically definitive
MS with a relapsing remitting or secondary progressive
disease course [8, 9]. None of the patients was using
immunomodulatory medication. Patients were relapse free
for at least 4 weeks and had not taken corticosteroids
4 weeks prior to the first MRI and during the study period.
Disability was assessed with the Expanded Disability
Status Scale (EDSS), which gives a score ranging from 0 to
10 with higher scores, indicating more disability [10].
1H-MR spectroscopy
MRI scans of the brain were obtained at baseline and after
4 weeks at a 3.0-T unit (Philips, Best, The Netherlands).
1H-MR spectroscopic imaging was preceded by the
acquisition of a transverse multiple-slice MRI series in
order to position the volume of interest (VOI). The
standard transmitter/receiver coil was used, and the
volume localisation was done by a combination of slice
selection and 2D phase encoding with outer volume
suppression with 12 rest slabs. All scan parameters were
the same: TE=144 ms, TR=2.5 s, FOV=230 mm, slice
thickness=20 mm, matrix=24×24, and turbo factor=3.
Total scan time was around 8 min.
Group 1 was scanned around the lateral ventricles
with some cerebrospinal fluid included in the VOI
(Fig. 1a). Group 2 was scanned above the lateral
ventricles with no cerebrospinal fluid included in the
VOI (Fig. 1b). Individual anatomic landmarks were used
for voxel repositioning.
Fig. 1 Sagittal MRI images showing the volume of interest scanned
in group 1 (a) and group 2 (b) with an axial image (c) displaying the
grey (inner 12) and white matter (outer 12 in both hemispheres)
voxels
1737To select voxels that mainly contained grey matter, 12
spectroscopic imaging (SI) voxels were selected in the
midline grey matter in each subject (Fig. 1c). To select
voxels that mainly contained white matter, 24 SI voxels
were selected (12 in each hemisphere) in the deep white
matter in each subject (Fig. 1c). Metabolite peak areas of
NAA and Cho were determined with the manufacturer’s
software (Philips SPECTROVIEW) and are expressed as
ratios to Cr. All voxels were visually checked for quality of
the spectra and quality of the fitting of the peak areas and
rejected if inaccurate according to the opinion of the two
observers.
In every patient the NAA/Cr and Cho/Cr ratios per voxel
were determined, and average ratios of the voxels in grey
and white matter were calculated.
Statistical analysis
Reproducibility was tested by a coefficient of variation
CV ¼ 100*standarddeviationof themeandifference ð

p
2*pooledmeanvalues ½  Þ [11]. Changes in grey matter
and white matter after 4 weeks and differences between
baseline grey and white matter NAA/Cr ratios in patients
were tested with paired t-tests. Differences between baseline
greymatterandwhitematterNAA/Crratios ofthetwoVOIs
were tested with unpaired t-tests.
Results
Baseline characteristics of the patients are shown in
Table 1. Patients were scanned after a mean ± standard
deviation of 27.3±2.2 days. The mean number of excluded
voxels was 1.51±2.93 for NAA/Cr and 4.54±5.40 for Cho/
Cr (out of 36 voxels). White matter NAA/Cr and Cho/Cr
ratios were higher than grey matter ratios (Table 2). The
mean NAA/Cr did not change in either white matter orgrey
matter in both groups after 4 weeks (Table 2). The NAA/Cr
ratios in grey and white matter were significantly higher in
the group scanned with the ventricles partially included
(p<0.001). Mean Cho/Cr in white and grey matter was 1.14
and 1.07 in group 1 and 0.98 and 0.92 in group 2
(p<0.001). Overall, the CV for NAA/Cr and Cho/Cr was
3.5% and 4.1% for white matter and 4.8% and 5.2% for
grey matter. In group 1, the CVs of NAA/Cr in white matter
and grey matter were 4.3% and 5.7%, and in group 2, 2.5%
and 3.7%.
Discussion
Several small clinical trials in MS patients have used NAA/
Cr ratios at the centrum semiovale as surrogate outcome
measure [12–16]. Narayanan et al. reported an increase in
NAA/Cr in ten relapsing MS patients after being treated
Table 2 The NAA/Cr ratios in
the centrum semiovale at week
0 and week 4: mean (SD)
*p value: comparison week 0
with week 4
#p<0.001: comparison of grey
matter with white matter
SD = standard deviation
Week 0 Week 4 p- value
*
All (N=35) NAA/Cr white matter 2.27 (0.26) 2.26 (0.25) 0.60
NAA/Cr grey matter 1.90 (0.23)
# 1.88 (0.21) 0.42
Cho/Cr white matter 1.05 (0.13) 1.03 (0.15) 0.11
Cho/Cr grey matter 0.98 (0.12)
# 0.98 (0.13) 0.60
Group 1 (N=15) NAA/Cr white matter 2.45 (0.26) 2.45 (0.25) 0.82
NAA/Cr grey matter 2.08 (0.23)
# 2.03 (0.20) 0.30
Group 2 (N=20) NAA/Cr white matter 2.14 (0.15) 2.13 (0.14) 0.53
NAA/Cr grey matter: 1.76 (0.11)
# 1.77 (0.12) 0.87
Table 1 Characteristics of the
patients
SD = standard deviation; IQR =
interquartile range
All Group 1 Group 2
Number 35 15 20
Gender: male 16 (46%) 8 (53%) 8 (40%)
Disease course: relapsing remitting/
secondary progressive
31/4 13/2 18/2
Age: mean (sd) in years 40 (9) 43 (10) 37 (8)
Disease duration: mean (SD) in years 11 (7) 12 (9) 11 (6)
EDSS: median (IQR) 3.0 (1.5–4.0) 3.0 (1.5–4.5) 3.0 (2.0–4.0)
1738with interferon β for 12 months [12]. Khan et al. reported
an elevation of NAA/Cr in 18 patients in a large central
brain volume after 2 years of treatment with glatiramer
acetate [15]. An increase in NAA/Cr at the centrum
semiovale in 11 MS patients after 2 weeks of treatment
with fluoxetine was observed [16]. These studies suggest
beneficial effects of therapy on axonal functioning or
integrity. However, interpretation of the results is hampered
by a lack of studies assessing reproducibility of NAA/Cr
measurements in MS patients.
One study in five healthy subjects, assessing intraday
and interday reproducibility of NAA/Cr ratios in the
centrum semiovale, found CVs ranging between 5.1% and
7.2% [17]. Another study found a mean CVof 3.7% in six
healthy subjects scanned twice, within 15 days apart, at a
large volume of supratentorial brain [18]. Our study for the
first time shows good short-term (4-week apart) repro-
ducibility of NAA/Cr ratio measurements in the centrum
semiovale of patients with MS.
In agreement with previous studies, NAA/Cr ratios in
grey matter were lower than in white matter [19, 20].
Patients scanned cranially of the ventricles had lower
NAA/Cr and Cho/Cr ratios compared to patients scanned
with the ventricles partially included. Since the corpus
callosum has the highest white matter NAA/Cr and Cho/Cr
ratios, the larger area of the corpus callosum included in the
VOI when scanning more caudally might explain this
difference [21]. This underlines the importance of correct
positioning of the VOI and voxel selection in longitudinal
MRS studies.
Our study indicates that NAA/Cr ratio measurements
with
1H-MRS at the centrum semiovale can be used as a
reliable surrogate marker of cerebral tissue integrity in
longitudinal MS studies. Selecting the VOI above the
ventricles is preferred above placing the VOI partially in
the ventricles.
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